Exavir Therapeutics Closes $4M Seed Financing


Exavir Therapeutics, a New York and Omaha, NE-based company dedicated to eliminating HIV, raised $4M in Seed funding.

The round was led by AlleyCorp with participation from Gilead Sciences.

The company intends to use the funds to expand its development efforts.

Led by Alborz Yazdi, co-founder and President, Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics.

HIV is one of the world’s most serious public health challenges. It is estimated that there are more than 37 million people living with HIV worldwide, and nearly 1.2 million people living with HIV in the United States alone. Over $30B is spent annually on antiretroviral HIV therapies worldwide.